|
 |
BenicarThis page contains recent news articles, when available, and an overview of Benicar but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Benicar (when available) Olmesartan Medoxomil, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Olmesartan Medoxomil does not have an active metabolite or possess uricosuric effects. For the treatment of hypertension Mechanism Of Action: Olmesartan Medoxomil competes with angiotensin II for binding at the also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decrease in systemic vascular resistance. News Articles on Olmesartan Medoxomil Daiichi Sankyo Looks For Acquisitions In Continued US Push - Dec 18, 2009 Daiichi, which had revenue of about $5.2 billion in the first half ended in September, has some presence in the US, selling blood pressure treatment Benicar ... Wall Street Journal Generic Name: Olmesartan Medoxomil, Olmetec - Nov 11, 2009 Benicar (generic name: Olmesartan, brand name: Olmetec) is a type of high blood pressure medicine called an angiotensin receptor blocker or ARB. ... Pattaya Daily News Strong Yen Slows Japanese Drug Firms' Recovery - Oct 30, 2009 ...lifted by growing sales of its drug for high blood pressure, Benicar, also known as Olmetec, and contributions from Indian generic drug unit, ... Wall Street Journal Forest Laboratories Inc. F2Q10 (Qtr End 30/09/09) Earnings Call Transcript - Oct 20, 2009 The brand continues to add new prescribers and gain repeat prescribers at a rate higher than experienced with Benicar, at a similar time period post-launch, ... Seeking Alpha (blog) Prescription Drugs: A 'Perfect Storm' That Almost Became a Killer - Oct 29, 2009 There was Valium for the vertigo, antidepressant Trozodone to counteract insomnia, Diazide and Benicar for her high blood pressure, potassium tablets, ... ADVANCE Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per ... - Oct 20, 2009 Contract revenue increased 7.2% to $50.6 million, principally due to Benicar (olmesartan medoxomil) co-promotion income of $46.6 million, an increase of ... Reuters Olmesartan medoxomil delayed microalbuminuria in patients with type 2 diabetes - Nov 4, 2009 Patients were assigned to either once-daily olmesartan medoxomil 40 mg (n=2200; Benicar, Daiichi Sankyo) or placebo (n=2200) and were followed for 3.2 years ... Endocrine Today Zacks Analyst Blog Highlights: Biogen Idec, Elan, UnitedHealth Group Inc ... - Oct 22, 2009 Contract revenue, consisting primarily of Benicar co-promotion income, increased 7.2% to $50.6 million. Forest's most recent product launch, Savella, ... Business Wire (press release) Brand Names/Synonyms: Benicar is also known by the following brand names and/or synonymsBenicar; CS 866; Olmesartan; Olmesartan Medoximil; Olmesartan Medoxomil; Olmetec Drug Category: Benicar is categorized under the following by the FDA: Antihypertensive Agents; ATC:C09CA08 Dosage Forms: ~13 hours Absorption: Bioavailability is about 26% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-imidazole-4-carboxylate |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
